Emmaus Life Sciences, Inc.
EMMA · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.02 | 0.04 | 0.00 |
| FCF Yield | -427.54% | -28.60% | -39.62% | -1.61% |
| EV / EBITDA | -35.29 | 9.78 | -7.58 | -8.61 |
| Quality | ||||
| ROIC | 18.93% | 154.41% | -35.92% | -14.48% |
| Gross Margin | 92.79% | 95.47% | 85.93% | 83.93% |
| Cash Conversion Ratio | 0.35 | 0.40 | 0.48 | 0.08 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.25% | 12.82% | -7.41% | -3.24% |
| Free Cash Flow Growth | -51.18% | 70.19% | -284.25% | 95.36% |
| Safety | ||||
| Net Debt / EBITDA | -34.70 | 8.31 | -5.24 | -2.17 |
| Interest Coverage | -0.34 | 0.48 | -1.31 | -1.98 |
| Efficiency | ||||
| Inventory Turnover | 0.73 | 0.78 | 1.09 | 0.75 |
| Cash Conversion Cycle | -450.04 | 182.08 | 300.51 | 473.57 |